Prescribing for chronic heart failure in Europe: does the country make the difference? A European survey

Pharmacoepidemiology and Drug Safety
Heidrun B SturmFlora M Haaijer-Ruskamp

Abstract

International differences in prescribing patterns for chronic heart failure (CHF) have been demonstrated repeatedly. It is not clear whether these differences arise entirely from patient characteristics or factors related to the country itself, such as health care systems or culture. We aim to assess the role of countries in this international variation, aside from the role of patient characteristics. In this European primary care practice survey (from 1999/2000) 11062 CHF patients from 14 countries were included. The influence of country (corrected for patient characteristics) on prescribed drug regimes was assessed by multinomial logistical regression. Prescribing of guideline-recommended drug regimes ranged from 28.1% in Turkey to 61.8% in Hungary. Including additional regimes justifiable by patients' co-morbidities, increased overall 'rational' prescribing by 11%, but differences among countries remained similar. Multivariate analysis for one-drug and two-drug regimes explained between 35% and 42% of the total variance, country contributed 7%-8% (p < 0.005). Countries determined the number of drugs used and the likelihood of individual drug regimes. For example, in Czech Republic digoxin alone was more likely to be given th...Continue Reading

References

Apr 20, 1999·European Heart Journal·D J van VeldhuisenJ R Hampton
Mar 29, 2000·Circulation·H M KrumholzJ A Spertus
Jun 1, 2000·International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care·C Chaix-CouturierP Durieux
Nov 10, 2001·BMJ : British Medical Journal·A C Freeman, K Sweeney
Oct 29, 2002·Patient Education and Counseling·Reginald DeschepperFlora M Haaijer-Ruskamp
Nov 30, 2002·Lancet·J G F ClelandUNKNOWN Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology
Mar 14, 2003·European Heart Journal·M KomajdaUNKNOWN Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology
Jul 24, 2003·Family Practice·A van den Brink-MuinenM Peltenburg
Dec 6, 2003·The New England Journal of Medicine·Haiden A HuskampRichard G Frank
Aug 11, 2004·European Journal of Heart Failure·Jorg MuntwylerFerenc Follath
Aug 9, 2005·European Journal of Heart Failure·Heidrun B SturmWiek H van Gilst

❮ Previous
Next ❯

Citations

Jun 24, 2010·BMC Health Services Research·Semiha DenktaşGouke Bonsel
Jan 2, 2013·International Journal of Health Care Quality Assurance·Eva BlozikMartin Scherer
Aug 24, 2013·Journal of the American Medical Directors Association·Tomas WelshAdam L Gordon
Mar 30, 2013·European Journal of Heart Failure·Aldo P MaggioniUNKNOWN Heart Failure Association of the European Society of Cardiology (HFA)
Jun 30, 2016·European Heart Journal·Søren Lund KristensenJohn J V McMurray
Jul 30, 2016·International Psychogeriatrics·Sarah I M JanusSytse U Zuidema
Jan 3, 2013·Nephrology·Zulfikar Jabbar, Bart J Currie
Dec 6, 2014·Hospital Pharmacy·Jennifer LeeJ Aubrey Waddell
Sep 26, 2015·Hospital Pharmacy·Kyle E AdkinsJ Aubrey Waddell
Oct 30, 2008·The Annals of Pharmacotherapy·Johan C F van LuijnHubert G M Leufkens

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.